Efficacy of tetravalent dengue vaccine in Thai schoolchildren

The Lancet

Volumn 381, Issue 9872, 2013, Pages 1094-

  Moi, Meng Ling ^a   Takasaki, Tomohiko ^a   Kurane, Ichiro ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; FC RECEPTOR; NEUTRALIZING ANTIBODY; PLACEBO;

ANTIBODY TITER; AWARENESS; DENGUE; DENGUE VIRUS 2; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOGENICITY; LETTER; MONOCYTE; PRIORITY JOURNAL; RANDOMIZATION; SAMPLING ERROR; SEROTYPE; TARGET CELL; THAILAND; FEMALE; MALE; NOTE;

DENGUE; DENGUE VACCINES; FEMALE; HUMANS; MALE;

EID: 84875691390     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)60754-0     Document Type: Letter

References (5)

1. A Sabchareon, D Wallace, C Sirivichayakul et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial Lancet 380 2012 1559 1567
2. B Guy, B Barrere, C Malinowski, M Saville, R Tessyou, J Lang From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent vaccine Vaccine 29 2011 7229 7241
3. ML Moi, CK Lim, A Kotaki, T Takasaki, I Kurane Discrepancy in neutralizing antibody titers between plaque reduction neutralizing tests using FcgammaR-negative and FcgammaR-expressing BHK-21 cells Clin Vac Immunol 17 2010 402 407
4. ML Moi, CK Lim, KB Chua, T Takasaki, I Kurane Dengue virus infection-enhancing activity in serum samples with neutralizing activity as determined by using FcγR-expressing cells PLoS Negl Trop Dis 6 2012 e1536
5. ML Moi, CK Lim, A Kotaki, T Takasaki, I Kurane Detection of higher levels of dengue viremia using FcγR-expressing BHK-21 cells than FcγR negative cells in secondary infection but not in primary infection J Infect Dis 203 2011 1405 1414